webinar-series
Date: October 14, 2020
Time: 7:00 pm  to  8:00 pm

Presenters: Caroline Durand and Agnes Jaulent, PhD, espeRare

Duration: 60 minutes

Price: Free

For 30+ years, the National Foundation for Ectodermal Dysplasias (NFED) has led the charge to develop a treatment for the common type of ectodermal dysplasia, x-linked hypohidrotic ectodermal dysplasia (XLHED). For the past few years, we have worked with espeRare to help develop a unique, pre-natal treatment.

EspeRare plans to launch a clinical trial in Europe and then the United States to confirm preliminary, promising findings from Dr. Holm Schneider’s Trial to Cure. In this pre-recorded webinar, Dr. Jaulent will explain where the current research stands.

You will learn…

  • what ER-004, the protein replacement therapy, is
  • how it impacted the symptoms of XLHED in three babies treated in utero in Dr. Scheider’s study
  • the goals of the clinical trial and what it means for the ectodermal dysplasias community
  • the logistics of the clinical trial – when and where it will launch, how to enroll, what to expect
  • and more! 

About the Experts

Caroline Durand trained as a pharmacist (France) and has a chemical engineer (école polytechnique de Montréal, Canada). She was previously in charge of pharmaceutical affairs for a French biotech company. She has 10+ years of experience in the field of development and biomanufacturing and has held various positions in R&D, industrialization, and analytical development at Sanofi Pasteur (Lyon, France). At Esperare, Caroline is in charge of developing clinical and regulatory strategies, interacting with Health Authorities (EU/US) and also leading the development of new clinical programs.

Agnes Jaulent  is the Translational Project Leader for espeRare. She studied for her PhD in chemistry at Imperial College London and then completed her post doctoral studies at the LMB (Laboratory for Molecular Biology) in Cambridge, United Kingdom. She then joined a biotech company that specializes in offering discovery services to the pharma industry in the fields of peptide, protein and antibody discovery.  She is an expert in all fields pertaining to protein and peptide chemistry. At EspeRare, Agnes is, amongst other duties, responsible for the CMC aspects of the ER-004 project.

Check back after September 1 to register.

Please Note: This webinar was pre-recorded. If you register, a link to this recording will be send to you at 7 p.m. on October 14.

View All Upcoming Webinars

If you have any questions about this webinar, contact Kelley at Kelley@nfed.org or 618-566-2020.


Disclaimer: This webinar is not intended as a substitute for medical advice. Only a healthcare provider with a full medical history may determine the proper treatment options. Opinions shared do not necessarily reflect those of the NFED. Topics, speakers and date are subject to change.